Why GlaxoSmithKline plc, Resolution Limited And Rio Tinto plc Should Beat The FTSE 100 Today

GlaxoSmithKline plc (LON: GSK), Resolution Limited (LON: RSL) and Rio Tinto plc (LON: RIO) are on the way up.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finally, we have a bit of life in the FTSE 100 (FTSEINDICES: ^FTSE), with the UK’s main index up 32 points to 6,606 by late morning. The insurance sector is putting in a good day so far, and the recent mini-recovery among the miners has not run out of steam. UK inflation for July was pretty much bang on expectations too, which helped steady nerves.

But which shares are on the way up? Here are three helping support the FTSE 100 today:

GlaxoSmithKline

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares gained 20.7p (1.2%) to 1,686p this morning on the news that the HIV treatment Tivicay has been given approval by the US Food and Drug Administration in 50mg tablet form. The drug is made by HIV specialist ViiV Healthcare, which is part-owned by GlaxoSmithKline, and the approval comes after a number of phase III trials.

GlaxoSmithKline shares have recovered well from a pessimistic 2012, though the price has been erratic of late — but it’s still up around 13% over the past 12 months. Based on forecasts for the year to December, the shares are on a P/E of a distinctly average 14, with a predicted 4.4% dividend yield on offer.

Resolution

First-half results sent Resolution shares up 11p (3.4%) to 335p, taking them up more than 50% over the past year. The life insurer saw pre-tax profit rise 17% £191m, with earnings per share (EPS) also up by 17%, to 13.26p. The firm, however, kept its interim dividend stable at 7.05p per share.

The gains were largely driven by new business in the UK, which rose by 41% to £89m. Internationally, things remained stable, with new business coming in at £21m against £22m a year previously. Chief executive Andy Briggs said that “We continue to make excellent operational progress in line with the clear and consistent strategy and value agenda of the Group“.

Rio Tinto

The recent rise in Chinese factory output has given the mining sector a boost this week, and Rio Tinto (LSE: RIO) (NYSE: RIO.US) gave us one of the biggest FTSE 100 risers by the time of writing today, with its shares up a further 64p (2%) to 3,257p. The shares had been on a slump since the start of 2013, losing around 30% between February’s peak and late June. But in the six weeks since, the price is back up 26% to bring it pretty much flat over the past 12 months.

There’s a small fall in EPS forecast for the full year, but a predicted return to earnings growth in 2014 would drop the P/E down to under 9. Meanwhile, there’s a likely dividend yield of around 3.7% on offer.

Finally, if you’re looking for investments that should take you all the way to a comfortable retirement, I recommend the Fool’s special new report detailing five blue-chip shares. They’ll be familiar names to many, and they’ve already provided investors with decades of profits.

But the report will only be available for a limited period, so click here to get your hands on these great ideas — they could set you on the road to long-term riches.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

I bought 1,779 Legal & General shares 2 years ago – see how much dividend income I’ve got since

Harvey Jones holds Legal & General shares and has been pretty underwhelmed by their performance so far. The dividend is…

Read more »

Middle-aged black male working at home desk
Investing Articles

Is the FTSE 100 set to soar? Here are 3 ways to aim to cash in

My outlook for the FTSE 100 is definitely brightening as we get deeper into 2025. How can we make the…

Read more »

Investing Articles

£10k invested in NatWest shares on the ‘Liberation Day’ dip is today worth…

Harvey Jones looks at how NatWest shares have been knocked off course during recent market turbulence, but are now bouncing…

Read more »

Tariffs and Global Economic Supply Chains
US Stock

£5,000 invested in Nvidia stock just before the tariff news is now worth…

Jon Smith talks through the erratic movements in Nvidia stock over the past six weeks and reveals where an investor…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

3 high-yield passive income stocks to consider buying right now

These stocks with big dividend yields look very tempting. Passive income investors could do well to consider taking the plunge.

Read more »

Handsome young non-binary androgynous guy, wearing make up, chatting on his smartphone, carrying shopping bags.
Investing Articles

Is a motley collection of businesses holding back this FTSE 100 stock?

Andrew Mackie explains why he's remained loyal to this FTSE 100 stock despite several of its businesses continuing to struggle…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

3 top growth stocks driving wealth in my Stocks and Shares ISA

Our writer shines a light on a trio of outperforming growth firms in his Stocks and Shares ISA portfolio. They're…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Here’s where analysts expect the Lloyds share price to be a year from now

The Lloyds share price has fared well so far in 2025. But with some big issues on the horizon, can…

Read more »